Regulus Therapeutics (RGLS) Projected to Post Earnings on Thursday

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) is expected to be issuing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.20). During the same period last year, the business posted ($0.40) EPS. On average, analysts expect Regulus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Regulus Therapeutics Trading Down 0.1 %

NASDAQ:RGLS traded down $0.01 during trading hours on Tuesday, hitting $7.85. The company had a trading volume of 250,390 shares, compared to its average volume of 869,887. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $8.20. The company has a 50-day moving average of $2.24 and a 200 day moving average of $1.71. The company has a market cap of $519.68 million, a P/E ratio of -7.33 and a beta of 0.49.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partnrs cut Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, May 1st. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, March 14th. Finally, Leerink Partners reiterated a "market perform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Regulus Therapeutics presently has an average rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.